BioAxone BioSciences has acquired the complete patent portfolio to protect Cethrin, including issued U.S. patents and patent applications (and foreign counterparts) encompassing composition of matter as well as therapeutic uses of Cethrin and small molecule inhibitors of Rho. The composition of matter patents protect Cethrin as well as the proprietary transport enhancement peptide.
Our novel and effective transport sequence is available to license. Our transport sequence allows protein drugs to penetrate cells by a mechanism that is not receptor mediated, and does not show the toxicity that has been associated with some of the other transport sequences.
BioAxone holds an issued patent on novel small molecule Rho kinase inhibitors. These inhibitors are available to license.